Drupal.behaviors.print = function(context) {window.print();window.close();}>
RXi Ends UMMS Licenses for 'Non-Core' RNAi Tech But Stays Focused on RNAi While Partner Searching
August 18, 2011
RXi Ends UMMS Licenses for 'Non-Core' RNAi Tech But Stays Focused on RNAi While Partner Searching
Full-text access for premium subscribers only.
Existing premium subscribers
login here
.
New to GenomeWeb?
Register here
quickly.
Related Stories
RXi Acquires Ownership of Previously Licensed RNAi Delivery Technology
October 1, 2009 / Gene Silencing News
People in the News: Paul Dorman, Curtis Lockshin
April 25, 2013 / Gene Silencing News
Following Private Placement, RXi Has Funds to Last into 2015
April 4, 2013 / Gene Silencing News
RXi Releases Blinded Phase I Data Hinting at Efficacy of Anti-Scarring Drug, On Track for Phase II
February 21, 2013 / Gene Silencing News
RXi Begins Second Phase I Trial of Anti-Scarring Drug
December 6, 2012 / Gene Silencing News